Ductal Carcinoma in Situ (DCIS) is a condition where the cells lining the milk ducts (the channels in the breast that carry milk to the nipple) are cancerous, but stay contained within the ducts without growing through into the surrounding breast tissue. DCIS may affect just one area of the breast, but can be more widespread and affect different areas at the same time. Sometimes DCIS may be described as pre-cancerous, pre-invasive, non-invasive, or intraductal cancer.
Findings by a researcher at The Cancer Institute of New Jersey highlighting the benefit of a shortened radiation course for patients with the most common type of non-invasive breast cancer are part of a feature article in the journal Cancer due out tomorrow.
Women with ductal carcinoma in situ-DCIS-who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease, according to a study published online March 11 in the Journal of the National Cancer Institute.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer. The researchers saw such a striking decrease, they believe they also have uncovered indirect evidence that hormones promote breast tumor growth.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment. While both treatments have been proven to lower the risk of recurrence in the breast, neither has been shown to improve survival, and both carry potentially serious risks.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike.
Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.
A new study of women who have been diagnosed with ductal carcinoma in situ (D.C.I.S.), may help personalize cancer treatment required by the women.
Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.
A new analysis has found that women with medium or low levels of income are particularly susceptible to anxiety and depression after being diagnosed with the precancerous breast condition, ductal carcinoma in situ (DCIS).
New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.
Dr. Jocelyn Rapelyea, Associate Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., demonstrated how occult lesions identified with Breast-Specific Gamma Imaging (BSGI) can be localized utilizing multi-modality imaging for needle biopsy as well, as for pre-operative localization today at the annual meeting of the Radiological Society of North America (RSNA).
Results of a large-scale clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) provide the first strong evidence of the benefit of annual screening ultrasound for women with dense breasts who are at elevated risk for breast cancer. In addition, the study confirmed that MRI is highly sensitive in depicting early breast cancer.
Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the detection of ductal carcinoma in situ (DCIS), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.
Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine.
Reporting online in the American Journal of Pathology, researchers from the Kimmel Cancer Center at Jefferson have implicated the loss of a stromal protein called caveolin-1 as a major new prognostic factor in patients with breast cancer, predicting early disease recurrence, metastasis and breast cancer patient survival.
A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine.
A University of Minnesota cancer surgeon and researcher has found a dramatic increase in the number of women diagnosed with the earliest stage of breast cancer choosing to have both breasts surgically removed.